Biomarker intelligence
Source-reviewed
Evidence reviewed 15 Oct 2026
Among older community-dwelling adults, poorer performance on the Short Physical Performance Battery, a set of balance, walking and chair-rise tests, was associated with higher mortality and nursing-home admission after adjustment for other factors. This was observational prediction, not a treatment comparison. It does not show that raising a person’s test score will prevent either outcome.
Boundary: Residual confounding and limited transportability; no clinically validated surrogate or treatment-guidance utility shown.
Biomarker intelligence
Source-reviewed
Evidence reviewed 2 Oct 2026
Circulating taurine is not supported as a universal, consistently declining marker of human aging.
Boundary: Age, activity, frailty and cohort context differ; association is not causation.
Biomarker intelligence
Source-reviewed
Evidence reviewed 2 Oct 2026
GrimAge and GrimAge2 are distinct mortality-trained DNA methylation predictors with overlapping cohort lineage.
Boundary: Prediction does not establish treatment benefit; samples are not unique people.
Biomarker intelligence
Source-reviewed
Evidence reviewed 2 Oct 2026
Cardiorespiratory fitness is prognostic; Generation 100 did not demonstrate a combined-exercise mortality advantage over active controls.
Boundary: VO2peak in this trial is not verified VO2max for everyone or a validated longevity surrogate.
Biomarker intelligence
Source-reviewed
Evidence reviewed 2 Oct 2026
Gait speed is prognostic; LIFE separately showed reduced loss of 400-m walking ability with structured physical activity.
Boundary: This does not validate every gait-speed change as a longevity surrogate.
Biomarker Intelligence
Source-reviewed
Evidence reviewed 9 Jul 2026
Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.
Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.
Biomarker Intelligence
Source-reviewed
Evidence reviewed 15 Jul 2026
Research-stage DNA methylation age and pace-of-aging measures with bounded utility claims.
Boundary: Does not establish diagnosis, clinical utility or a definitive biological-age reading.